[go: up one dir, main page]

WO1996007421A3 - An antiulcer medicine comprising a protein possessing all growth factor activity and a proton pump inhibitor - Google Patents

An antiulcer medicine comprising a protein possessing all growth factor activity and a proton pump inhibitor Download PDF

Info

Publication number
WO1996007421A3
WO1996007421A3 PCT/JP1995/001772 JP9501772W WO9607421A3 WO 1996007421 A3 WO1996007421 A3 WO 1996007421A3 JP 9501772 W JP9501772 W JP 9501772W WO 9607421 A3 WO9607421 A3 WO 9607421A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
proton pump
pump inhibitor
factor activity
protein possessing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1995/001772
Other languages
French (fr)
Other versions
WO1996007421A2 (en
Inventor
Hiroshi Satoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to AU33991/95A priority Critical patent/AU3399195A/en
Publication of WO1996007421A2 publication Critical patent/WO1996007421A2/en
Publication of WO1996007421A3 publication Critical patent/WO1996007421A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a medicine which comprises a combination of a protein possessing cell growth factor activity with a proton pump inhibitor which enhances the preventive and therapeutic effect of either drug used alone against ulcers, particularly peptic ulcers.
PCT/JP1995/001772 1994-09-09 1995-09-06 An antiulcer medicine comprising a protein possessing all growth factor activity and a proton pump inhibitor Ceased WO1996007421A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33991/95A AU3399195A (en) 1994-09-09 1995-09-06 An antiulcer medicine comprising a protein possessing cell growth factor activity and a proton pump inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6/215717 1994-09-09
JP21571794 1994-09-09

Publications (2)

Publication Number Publication Date
WO1996007421A2 WO1996007421A2 (en) 1996-03-14
WO1996007421A3 true WO1996007421A3 (en) 1996-04-11

Family

ID=16677015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/001772 Ceased WO1996007421A2 (en) 1994-09-09 1995-09-06 An antiulcer medicine comprising a protein possessing all growth factor activity and a proton pump inhibitor

Country Status (2)

Country Link
AU (1) AU3399195A (en)
WO (1) WO1996007421A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667039A1 (en) * 2006-10-17 2008-04-24 Ranbaxy Laboratories Limited Multiple unit tablet compositions of benzimidazole compounds
EP4356904A1 (en) * 2022-10-19 2024-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. A capsule comprising lansoprazole

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMAI S ET AL: "Effect of proton pump inhibitor, in combination with epidermal growth factor, on the healing of chronic gastric ulcer in submandibular gland removed rats", NIPPON RINSHO, JAN 1992, 50 (1) P39-44, JAPAN *
KASUGAI K ET AL: "H2-receptor antagonist and proton pump inhibitor augment an EGF action in gastric juice of rats", GASTROENTEROLOGY, 106 (4 SUPPL.). 1994. A818. *

Also Published As

Publication number Publication date
WO1996007421A2 (en) 1996-03-14
AU3399195A (en) 1996-03-27

Similar Documents

Publication Publication Date Title
CA2131316A1 (en) A thrombin blood fraction for use in a medical procedure
AU693073B2 (en) Systems and methods for communicating with ambulatory medical devices such as drug delivery devices
MY129973A (en) Sulphonylbenzyl-substituted pyridones.
WO1992018160A3 (en) Method for inhibiting adhesion of white blood cells to endothelial cells
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
AU5058198A (en) Device for ionophoresis comprising at least a membrane electrode assembly, for the transcutaneous administration of active principles to a subject
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
AU7200387A (en) Device for self-administration of physiologically active substances, with prevention of overdosing
IE891798L (en) Novel ó-glucosidase inhibitors
AU8163394A (en) Treatment of diabetes by administration of myo-inositol
AU3382995A (en) Combined preparation for the therapy of immunological diseases
CA2186269A1 (en) Wound healing
NO973548L (en) Treatment of diabetic neuropathy
AU7313896A (en) Pharmaceutical composition containing an activin or inhibin stimulator
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
WO1997030714A3 (en) Topical pharmaceutical composition containing heparin
WO1996007421A3 (en) An antiulcer medicine comprising a protein possessing all growth factor activity and a proton pump inhibitor
AU591892B2 (en) Peptides
WO1997017072A3 (en) Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system
EP0161816A3 (en) Urogastrone
AU3374593A (en) Improved high protein liquid nutrition for patients with elevated wound healing requirements
AU7854094A (en) Use of amiodarone for the treatment of heart failure
EP0330218A3 (en) Inhibitors of lysyl oxidase
AU2267188A (en) One-way valve, method for the production thereof and the use of the valve
AU4332889A (en) Active attenuation system for medical patients

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 535290

Date of ref document: 19951102

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase